- Home
- ANF vs DNLI Comparison
ANF vs DNLI Comparison
Compare ANF & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANF | DNLI |
|---|---|---|
| Founded | 1892 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANF | DNLI |
|---|---|---|
| Price | $139.55 | $18.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 20 |
| Target Price | ★ $163.55 | $36.06 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.59 | N/A |
| Revenue | ★ $5,266,292,000.00 | N/A |
| Revenue This Year | $4.99 | N/A |
| Revenue Next Year | $4.26 | $156.11 |
| P/E Ratio | $25.30 | ★ N/A |
| Revenue Growth | ★ 6.42 | N/A |
| 52 Week Low | $65.45 | $13.75 |
| 52 Week High | $155.22 | $27.30 |
Technical Indicators
Market Signals| Indicator | ANF | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 58.97 | 29.11 |
| Support Level | $90.90 | $18.38 |
| Resistance Level | $154.90 | $20.84 |
| Average True Range (ATR) | 4.67 | 0.81 |
| MACD | -0.45 | -0.07 |
| Stochastic Oscillator | 77.71 | 12.89 |
Price Performance
Historical ComparisonAbout ANF Abercrombie & Fitch Company
Abercrombie & Fitch Co is a digitally led, omnichannel retailer offering apparel, personal care products, and accessories for men, women, and kids through company-owned stores, digital channels, and third-party arrangements. The company operates through three geographic segments: Americas, the maximum revenue generator; Europe, the Middle East and Africa (EMEA); and Asia-Pacific (APAC). Its brand families include Abercrombie brands and Hollister brands. The Americas segment covers North and South America, EMEA includes Europe, the Middle East and Africa, and APAC includes the Asia-Pacific region, including Asia and Oceania.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.